Strategy

Jun 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
No matter how the Supreme Court rules on healthcare reform, the accountable care model will stick around. To play ball with ACOs, drug companies will need to throw a different pitch.
Jun 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Pharm Exec convened a panel of heavy hitters in business development to crack the bat on best practices in licensing and M&A for the year ahead.
Jun 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
May 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Will changes to the P&R system in the UK finally put some real metrics behind the elusive concept of value?
Apr 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Too often in M&A or product-linked carve-outs, executives overlook the complexities of disentangling operations and the effort required for regulatory re-registration and labeling changes.
Mar 12, 2012
Pharmaceutical Executive
With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition.
Mar 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Making real connections that resonate with audiences in a digital world is a fine art, especially in the heavily regulated world of Big Pharma
Mar 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Our annual press audit finds that the big news in 2011 for pharma was ... no news.
Feb 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Pharm Exec's Brand of the Year: Abbott's Humira
Feb 01, 2012
Pharmaceutical Executive
Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".
native1_300x100
lorem ipsum